Overview

A Study to Investigate the Response of Participants With Type 2 Diabetes Mellitus on Once-Weekly Retatrutide to Hypoglycemia

Status:
RECRUITING

Trial end date:
2026-05-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to measure the effect of retatrutide versus placebo, administered every week, on time to recovery from hypoglycemia during hypoglycemic clamp in participants with Type 2 Diabetes Mellitus (T2DM) following 16 weeks of treatment.

Phase:

PHASE1

Details

Lead Sponsor:

Eli Lilly and Company

Treatments:

retatrutide